IASLC TTLC 2022 | Moving immunotherapy and targeted therapies to the frontline setting

Jia Luo, MD, Dana-Farber Cancer Institute, Boston, MA, provides an overview of the benefits of administering immunotherapy and targeted therapies in patients with lung cancer in earlier settings. Trials including the IMpower010 trial (NCT02486718) , which assessed neoadjuvant atezolizumab plus chemotherapy, and the approval of osimertinib, an EGFR-inhibitor for non-small cell lung cancer, have demonstrated the efficacy of neoadjuvant immunotherapy and targeted therapies. Dr Luo additionally highlights the need for optimized endpoints such as pathologic complete response (pCR) to assess these treatments. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).